ClinicalTrials.gg
CompletedNCT06955741Updated Oct 1, 2025

A Study to Assess Drug Levels, Tolerability and Absolute Biological Availability of Single-dose of BMS-986446 in Healthy Participants

A Phase 1 interventional study of BMS-986446 IV and BMS-986446 SC in Healthy Volunteer, sponsored by Bristol-Myers Squibb. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-01.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to assess drug levels, tolerability and absolute biological availability of single subcutaneous dose of BMS-986446 in healthy participants

02

Conditions studied

  • Healthy Volunteer

Keywords

  • Bioavailability Study
  • Subcutaneous Injection
  • Anti-MTBR Tau Monoclonal Antibody
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have a (BMI) of 18.0 to 30.0 kg/m2.
  • Participants must be healthy as determined by medical history, physical examination, neurological examination, vital signs, 12-lead , C-SSRS, and clinical laboratory evaluations.

Exclusion criteria

Exclusion Criteria:

  • Participants must not have gastrointestinal, renal, hepatic, broncho-pulmonary, neurological, psychiatric, cardiovascular, endocrinological, immune-mediated disorder, hematological, ongoing allergic disorder requiring treatment, metabolic disorder, cancer, or cirrhosis.
  • Participants must not have prior exposure to BMS-986446 (PRX005).
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Arm A

    Drug: BMS-986446 IV · Drug: Acetaminophen · Drug: Loratadine

  • Experimental
    Arm B

    Drug: BMS-986446 SC · Drug: Acetaminophen · Drug: Loratadine

Interventions

  • Specified dose on specified days was administered intravenously (IV).

  • Specified dose on specified days was administered subcutaneously (SC).

  • Specified dose on specified days

  • Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Geometric Mean Ratio (GMR) of Maximum Observed Serum Concentration (Cmax) of BMS-986446 Administered IV versus SC

    Time frame: Up to approximately Day 85

  2. GMR of Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) of BMS-986446 Administered IV versus SC

    Time frame: Up to approximately Day 85

  3. GMR of Area Under the Serum Concentration-time Curve From Time Zero to 672 Hours (AUC(0-672)) of BMS-986446 Administered IV versus SC

    Time frame: Up to approximately Day 85

  4. Absolute Bioavailability (F) Estimated From GMR of AUC(INF) of BMS-986446 Administered as SC versus IV Infusion

    Time frame: Up to approximately Day 85

Secondary outcomes

  1. Number of Participants With Adverse Events (AEs)

    Time frame: Up to approximately Day 85

  2. Number of Participants With Serious Adverse Events (SAEs)

    Time frame: Up to approximately Day 85

  3. Number of Participants With AEs Reported Related to BMS-986446

    Time frame: Up to approximately Day 85

  4. Number of Participants With Clinically Significant Vital Sign Abnormalities

    Time frame: Up to approximately Day 85

  5. Number of Participants With Clinically Significant Changes in 12-lead Electrocardiogram (ECG)

    Time frame: Up to approximately Day 85

  6. Number of Participants With Clinically Significant Physical Examination (PE) Abnormalities

    Time frame: Up to approximately Day 85

  7. Number of Participants With Suicidality as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)

    Time frame: Up to approximately Day 85

  8. Number of Participants With Clinically Significant Laboratory Assessment Abnormalities

    Time frame: Up to approximately Day 85

  9. Cmax of BMS-986446

    Time frame: Up to approximately Day 85

  10. AUC(0-T) of BMS-986446

    Time frame: Up to approximately Day 85

  11. AUC(0-672) of BMS-986446

    Time frame: Up to approximately Day 85

  12. Area Under the Serum Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) of BMS-986446

    Time frame: Up to approximately Day 85

  13. Time of Maximum Observed Serum Concentration (Tmax) of BMS-986446

    Time frame: Up to approximately Day 85

  14. Apparent Terminal Serum Half-life (T-HALF) of BMS-986446

    Time frame: Up to approximately Day 85

  15. Total Body Clearance in IV Infusion (CLT) of BMS-986446

    Time frame: Up to approximately Day 85

  16. Apparent Total Body Clearance in SC Administration (CLT/F) of BMS-986446

    Time frame: Up to approximately Day 85

  17. Volume of Distribution of Terminal Phase in IV Infusion (Vz) of BMS-986446

    Time frame: Up to approximately Day 85

  18. Apparent Volume of Distribution of Terminal Phase in SC Administration (Vz/F) of BMS-986446

    Time frame: Up to approximately Day 85

  19. Number of Participants With Anti-drug Antibody Development

    Time frame: Up to approximately Day 85

  20. Local Tolerance Evaluation SC Administration of BMS-986646 Assessed by Questionnaire

    Participant-reported response will be obtained using questionnaires that assess for pain (using a Numeric Rating Scale), itching, burning, pressure, and soreness/tenderness at the site injection.

    Time frame: Up to approximately Day 85

07

Study locations

2 sites
  • Local Institution - 0001
    Anaheim, California 92801, United States
  • Local Institution - 10000
    Anaheim, California 92801, United States
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myers Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.htm

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2025 to primary completion in Sep 2025, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2025
First posted
May 2, 2025
StartActual
May 5, 2025
Primary completionActual
Sep 11, 2025
CompletionActual
Sep 11, 2025
Last update
Oct 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06955741
Responsible party
Sponsor
First posted
May 2, 2025
Start date
May 5, 2025
Primary completion
Sep 11, 2025
Completion
Sep 11, 2025
Last update
Oct 1, 2025

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Moponetug

Start the discussion